The Other Exponential
No. 113 | Everyone is watching AI. The other exponential is happening inside our own bodies.
"Live long and prosper." — Spock, Star Trek (1967)
Last week, while the timeline argued about whether the newest AI model had a mind, a federal advisory panel changed, with almost no notice, what Americans are allowed to put in their bodies. Six of the seven peptides on its docket, compounds like BPC-157 and TB-500, moved one step further through the regulatory process. It barely made a headline. We keep looking for the future in software. It has been arriving in biology all along.
A disclosure before I go further. We are investors in Feel Peptides, so weigh what follows accordingly. I would write this anyway.
Start with the word, because almost nobody can define it. A peptide is a short chain of amino acids. Think of it as a message. Insulin is one, and you already trust it with your life. Your body sends thousands more, telling tissue to repair and inflammation to settle. Many of the medicines we grew up with forced the body into compliance. This kind speaks its language back to it.
GLP-1 was the proof. Roughly one in eight American adults now takes one, a share that has doubled in eighteen months, self-injected at home, with none of the resistance the experts predicted. A whole country crossed the needle barrier without flinching. Once you watch your own biology answer a weekly signal, and I have, something shifts.
For all of medical history the job was to fix you after you broke. Peptides ask a different question altogether. Less repair shop, more software update. The idea still unsettles doctors. Consumers are already there.
The compounds crowding in behind GLP-1 carry gray-market music, BPC-157, Semax, Epitalon, MOTS-c, names you used to buy from a stranger with an anime avatar and a supplier in Shenzhen. Some target repair, others cognition or sleep or metabolism. They are early, uneven, and mostly unproven, and three curves are converging anyway. Synthesis got cheap. Manufacturing got trustworthy. GLP-1 made the needle ordinary. When those meet, a fringe becomes a market.
Here is my claim.
The other exponential is biology, and I spend most of my week around AI founders.
AI changes what we can make. Biology changes what we are.
One rewrites the tools. The other rewrites the toolmaker.
We are still asking whether AI will truly change how people work. Tens of millions of people, meanwhile, have already started reshaping their bodies around a weekly shot, no mandate, no debate. The hardest thing in technology was never the breakthrough. It is getting one ordinary person to change one daily habit. Biology did that at national scale while software was still writing think pieces about disruption.
Let me be precise, because the sharpest readers will push here. GLP-1 is proven. Most of these peptides are not, not yet. So what matters is not any single molecule. It is that people have changed. Those tens of millions have agreed to manage their own biology, and they are not going back. Every one of them is a vote that health has become something you do on purpose, not something that merely happens to you. Whether today’s compounds earn their claims is an open question. That a willing market is waiting for the ones that do is not.
I am old enough to be cynical, and I am choosing to spend that cynicism elsewhere. For most of human history your body was a fate. You were handed a metabolism, an attention span, a slow decline, and you lived inside the verdict. That is the thing quietly ending. The body is becoming something you can edit.
We spent a century building smarter tools. We are about to spend one improving the toolmaker. This time the future is not happening to us. It is happening in us.
The children being born now will find it strange that we ever simply accepted the body we were handed. Tuning it will feel as ordinary to them as straightening their teeth. They will not call it a revolution. They will call it Tuesday.
That is how the biggest shifts arrive, not as headlines but as habits nobody thinks to question.
And getting to watch one happen is a gift.
It is a good time to be alive.
If you are building in the peptide space, we want to talk. Operators are standing by. brian@sugarcap.com